HomeTOP STORIESLexeo climbs after regulatory update on Friedreich ataxia drug Lexeo climbs after regulatory update on Friedreich ataxia drug By rogerjudd October 7, 2025 FacebookTwitterPinterestWhatsApp Post Content Previous articleCitadel’s Griffin says U.S. on ‘sugar high’ as investors rush to goldNext articleJames Hardie pops as Q2 earnings seen above estimates latest articles Byrna projects 35%-40% revenue growth for 2025 as AI-driven advertising and retail expansion fuel demand Paramount Skydance Chief sees `lots of options’ for media deals SA analysts weigh in on the current government shutdown Gold, Silver And Platinum Surge: Are These Commodities Too Hot For Investors To Touch? | IBD Here are five top stocks to add to your watchlist today. Keystone Global Financial files for IPO of 1.25M shares explore more Byrna projects 35%-40% revenue growth for 2025 as AI-driven advertising and retail expansion fuel demand Paramount Skydance Chief sees `lots of options’ for media deals SA analysts weigh in on the current government shutdown Gold, Silver And Platinum Surge: Are These Commodities Too Hot For Investors To Touch? | IBD Here are five top stocks to add to your watchlist today. Keystone Global Financial files for IPO of 1.25M shares
